CEO Joshua T Brumm sells 42,305 shares ($761.1K) of CRESCENT BIOPHARMA (CBIO) via 10b5-1 plan; stock down -36.2% from 52-week high.
Joshua T Brumm, as CEO of Crescent BioPharma, sold 42,305 shares at $17.99 on 2026-06-22 as part of a pre-arranged 10b5-1 trading plan adopted on 2026-02-28, meaning this was a scheduled transaction rather than a discretionary decision. The sale reduced his holdings by 42,305 shares from 323,517 to 281,212 shares. The company faces significant operational headwinds: it generated only $1,039,000 in latest-quarter revenue while reporting a net loss of $23,283,000 and remains unprofitable on a full-year basis. The stock has declined -36.2% from its 52-week high of $27.41 to the current price of $17.50, and is down -15.6% over the past 30 days despite a +48.6% gain over 90 days. Since this transaction is scheduled under a 10b5-1 plan, the timing reflects administrative execution rather than insider discretion, and therefore should not be interpreted as a market-timing signal.